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Abstract
Interferons a and b (IFN-a/b) are type I interferons produced by the host to control microbial infections. However, the use of
IFN-a to treat hepatitis B virus (HBV) patients generated sustained response to only a minority of patients. By using HBV
transgenic mice as a model and by using hydrodynamic injection to introduce HBV DNA into the mouse liver, we studied
the effect of IFN-a/b on HBV in vivo. Interestingly, our results indicated that IFN-a/b could have opposite effects on HBV:
they suppressed HBV replication when viral load was high and enhanced HBV replication when viral load was low. IFN-a/b
apparently suppressed HBV replication via transcriptional and post-transcriptional regulations. In contrast, IFN-a/b
enhanced viral replication by inducing the transcription factor HNF3c and activating STAT3, which together stimulated HBV
gene expression and replication. Further studies revealed an important role of IFN-a/b in stimulating viral growth and
prolonging viremia when viral load is low. This use of an innate immune response to enhance its replication and persistence
may represent a novel strategy that HBV uses to enhance its growth and spread in the early stage of viral infection when the
viral level is low.
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Introduction
Interferon-a (IFN-a) and interferon- b (IFN- b) are type I
interferons, which are produced by the host in response to viral
infections to inhibit viral replication [1]. After binding to its
receptor, IFN-a/b activates the Janus kinase (JAK) and its
downstream signal transducer and activator of transcription
(STAT) and induces the expression of more than 300 IFN-
stimulated genes (ISGs) and many antiviral proteins [2,3]. IFN-a
has been used to treat viral infections including hepatitis B virus
(HBV), which chronically infects approximately 350 million
people in the world. Unfortunately, IFN- a generates sustained
virological response in only a minority of patients [4]. Little is
known why the majority of HBV patients do not respond to the
IFN-a therapy.
HBV is a small DNA virus that infects liver. Its genome is only
3.2 Kb in size and consists of four genes: the C gene codes for the
viral core protein that forms the viral capsid and a related protein
termed precore protein, which is the precursor of the secreted e
antigen (HBeAg); the S gene codes for the viral envelope proteins,
also known as surface antigens (HBsAg); the P gene codes for the
viral DNA polymerase; and the X gene codes for a regulatory
protein. To understand why IFN-a generates different responses in
HBV patients, we studied the effect of IFN-a/b on HBV
replication using mice as a model. Interestingly, we found that
interferons could suppress HBV replication when viral load is high
and enhance HBV replication when viral load is low. The
suppression of HBV replication by IFN-a/b apparently involves
both transcriptional and post-transcriptional regulations whereas
the enhancement of HBV replication by IFN-a/b is mediated by
transcription factors HNF3c and STAT3. This use of type I
interferons induced by its infection to enhance its replication thus
represents a novel strategy that HBV may use to stimulate its
growth and spread in the early stage of viral infection when the
viral level is still low.
Results
Opposite effects of IFN-a/b on HBV replication in HBV
transgenic mice
We have previously produced four HBV transgenic mouse lines
that carry either the wild type HBV genome (Tg05 and Tg08
mouse lines) or the mutated HBV genome that is incapable of
expressing only the HBV X protein (HBx) (Tg31 and Tg38 lines)
[5], which is a regulatory protein. These mouse lines contain
replicating HBV DNA in the liver and produce mature viral
particles in the blood (Figure S1A and S1B). To examine the
possible effects of IFN-a/b on HBV in vivo, HBV transgenic mice
were injected intravenously with the IFN-a/b inducer poly(I:C), or
with saline, which served as the control. Mice were sacrificed
12 hours or 24 hours after injection for the studies. The effect of
poly(I:C) on HBV DNA replication in the liver was analyzed by
Southern blot. The level of HBV DNA replicative intermediates
(RI) in the Tg05 mouse liver at 12 hours and 24 hours after
poly(I:C) injection was reduced by 54% and 80%, respectively
(Figure 1A). When the HBV RNA was analyzed by Northern-blot,
a slight reduction of the level by poly(I:C) was also observed,
particularly with the HBV C gene transcripts. When the HBV
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poly(I:C) was inapparent at 12 hours, likely due to the stability of
this protein. However, its reduction was apparent at 24 hours after
injection (Figure 1A). For the Tg38 mouse line, the HBV DNA in
the liver was also reduced in a time-dependent manner, although
by a lesser degree (36% and 61% reduction at 12 hours and
24 hours, respectively, after injection). The reduction of the HBV
RNA levels was not obvious. However, the core protein reduction
was apparent at the 24-hour time point (Figure 1A). In contrast to
Tg05 and Tg38 mouse lines, poly(I:C) increased the HBV DNA,
RNA and core protein levels in the liver of Tg31 and Tg08 mice
(Figure 1A). These results indicated that poly(I:C) could have
different effects on HBV, depending on the mouse lines.
To determine whether the effect of poly(I:C) on HBV was
mediated by interferons, we first tested whether poly(I:C) could
indeed induce the interferon response in all four mouse lines. Total
mouse liver RNA was isolated and analyzed for the expression of
29-59 oligoadenylate synthetase (29,59-OAS), a gene activated by
IFN-a/b, by semi-quantitative reverse transcription PCR (RT-
PCR). The expression of 29,59-OAS was indeed induced in the
liver of all four mouse lines, indicating the induction of interferon
response by poly(I:C) (Figure S2A). We next injected HBV
transgenic mice with antibodies directed against IFN-a/b one day
prior to the injection of poly(I:C). The administration of anti-IFN-
a/b antibodies, but not the control antibody, abolished the
induction of 29,59-OAS, indicating the ability of these anti-IFN-a/
b antibodies to inhibit the activities of IFN-a/b in the liver (Figure
S2B). Finally, we analyzed the effect of anti-IFN-a/b antibodies on
HBV replication. The administration of anti-IFN-a/b antibodies,
but not the control antibody, prevented poly(I:C) from reducing
the levels of HBV RI DNA, RNA and core protein in Tg05 and
Tg38 mice and from increasing their levels in Tg08 and Tg31
mice (Figure 1B). If anti-IFN-a and anti-IFN-b antibodies were
administered separately, the latter was found to be more efficient
than the former in blocking the effect of poly(I:C) (Figure S2C).
This result might be due to the preferential induction of IFN-b by
poly(I:C) [6], or the difference in activities of these two cytokines
[7]. We had also tested directly the role of IFN-a/b in the
regulation of HBV replication by injecting Tg05 and Tg31 mice
with IFN- a and IFN-b. Our results indicated that IFN- a had only
a slight effect on HBV in these two mouse lines whereas IFN-b
significantly suppressed HBV replication in Tg05 mice and
enhanced HBV replication in Tg31 mice (Figure S2D).
In the studies shown in Figure 1, HBV transgenic mice were
only treated with poly(I:C) for up to 24 hours. To determine
whether the effects of poly(I:C) on HBV could persist, we analyzed
its effects on HBV for one week. As shown in Figure S2E, the
effects of poly(I:C) on HBV could persist for one week, the
endpoint of the analysis.
Our results thus indicated that the effect of IFN-a/b on HBV
could vary depending on the mouse lines. This effect of IFN-a/b
on HBV is independent of the HBx protein, as Tg05 and Tg08
mice carried the wild-type HBV genome and yet responded in
opposite ways to IFN-a/b. Similarly, Tg31 and Tg38 carried the
X-null HBV genome and also responded differently to IFN-a/b.
However, there appeared to be a viral load-dependent effect, as
IFN-a/b suppressed HBV replication in Tg05 and Tg38 mice,
which produced higher levels of HBV, whereas they enhanced
HBV replication in Tg08 and Tg31 mice, which produced lower
levels of HBV (Figure S1A and S1B).
Viral load-dependent effect of IFN-a/b on HBV replication
To examine whether the effect of IFN-a/b on HBV is indeed
dependent on viral load, we performed the hydrodynamic
injection, which is a rapid and convenient method for gene
delivery into the mouse liver [8]. In this study, different amounts of
the 1.3mer, over-length HBV DNA genome were injected via the
tail vein into mice. Increasing the amount of HBV DNA in the
injection led to an increasing level of HBV RI DNA, HBV RNA
and the core protein in the liver until the amount of HBV DNA
reached 24 mg (Figure 2A). Further increase of the HBV DNA
amount to 32 mg for injection did not increase, but rather,
decreased HBV RI DNA, HBV RNA and core protein levels in
the mouse liver, perhaps due to the reduction in DNA delivery
efficiency (Figure 2A). There was a positive correlation between
the levels of HBV RI DNA in the liver and HBV titers in the sera
(Figure S3). To test whether the effect of poly(I:C) on HBV
replication is dependent on viral load, mice were injected with
ploy(I:C) three days after the hydrodynamic injection of HBV
DNA and sacrificed 24 hours later for HBV replication studies.
Poly(I:C) increased HBV DNA, RNA and core protein levels when
the HBV DNA used for the injection was 4, 8 or 14 mg. However,
poly(I:C) decreased HBV DNA, RNA and core protein levels
when the amount of HBV DNA used for the injection was 20, 24
or 32 mg (Figure 2A).
To determine whether the effect of poly(I:C) on HBV in this
hydrodynamic injection study was also mediated by IFN-a/b,w e
also injected mice with either the control antibody or the anti-IFN-
a/b antibodies. The control IgG had no effect on the increase of
HBV DNA, RNA and core protein levels induced by poly(I:C)
when mice were injected with 8 mg HBV DNA. However, this
increase was abolished by anti-IFN-a/b antibodies. Similarly,
although the control IgG had no effect on the decrease of HBV
DNA, RNA and core protein levels by poly(I:C) when mice were
injected with 20 mg HBV DNA, anti-IFN-a/b antibodies
diminished the suppressing effect of poly(I:C) on HBV (Figure 2B).
The results indicate that the effect of IFN-a/b on HBV is
dependent on viral load. They enhance HBV replication when
viral load in the serum is low and suppress HBV replication when
viral load is high. The viral DNA level in the serum that separates
these two opposite responses appears to be in the vicinity of 10
7
copies/ml (Figure S3), as the HBV replication was stimulated by
interferons when the viral DNA level in the serum was lower than
10
7 copies/ml whereas it was suppressed when the viral DNA level
was higher than 10
7 (Figure 2A and Figure S3).
Author Summary
Hepatitis B virus (HBV) is a major human pathogen that
can cause severe liver diseases including hepatitis, liver
cirrhosis and hepatocellular carcinoma. Approximately 350
million people worldwide are chronic carriers of this virus.
Type I interferons (IFNs), which include IFN-a and IFN-b, are
produced by the host to control microbial infections.
However, the use of IFN-a to treat HBV patients has
generated inconsistent results. By using mice as an animal
model, we have investigated the effect of type I IFNs on
HBV replication in vivo. Our results indicate that IFN-a/b
can suppress HBV replication when viral load is high and
enhance HBV replication when viral load is low. These
effects of IFN-a/b on HBV are due in part to their abilities
to regulate HBV gene expression. Our further studies
reveal an important role of IFN-a/b in stimulating viral
growth when viral load is low. This use of an innate
immune response to enhance its replication may represent
a novel mechanism that HBV uses to enhance its growth
and spread in the early stage of infection when the viral
level is still low.
Type I Interferons on HBV Replication
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mice by poly(I:C)
Previous studies indicated that IFN-a/b suppressed HBV
replication in transgenic mice that produced high levels of HBV
by inhibiting the assembly of the viral capsid or by accelerating their
degradation [9]. Our poly(I:C) injection results indicated that IFN-
a/b could also affect HBV RNA transcription or stability, as the
reduction of HBV RNA levels in the liver of mice that produced
high levels of HBV was also apparent after the injection of poly(I:C)
(e.g.,Figure2Aand2B).However,inmicethatproducedalowlevel
of HBV, IFN-a/b significantly increased the levels of both HBV C
gene and S gene RNA transcripts, suggesting that IFN-a/b might
enhance HBV replication in these mice by enhancing the
transcription of HBV genes, possibly by acting on the two HBV
Figure 1. Effects of IFN- a/b on HBV in mice. (A) Effects of poly(I:C) on HBV replication in transgenic mice. Four different HBV transgenic mouse
lines were used for the studies. To minimize the variations of the results, mice of the same lineage were pre-screened for their serum HBV e antigen
(HBeAg) levels, and only those with matched HBeAg levels were used for the studies. HBV transgenic mice were injected intravenously with saline
and sacrificed 24 hours later (i.e., 0 hour poly(I:C) treatment), or with 200 mg poly(I:C) and sacrificed 12 hours or 24 hours later. Total liver DNA was
isolated, digested with PvuII which does not cut into the HBV genome, and analyzed by Southern-blot for HBV DNA (top panel). The positions of HBV
transgene, which served as the loading control for Southern-blot, and the HBV RI DNA are marked. Total liver RNA was also analyzed for HBV RNAs by
Northern-blot (second panel from the top). C and S denote the HBV C gene and S gene RNA transcripts, respectively. For the RNA gel, 28S and 18S
rRNAs were stained with ethidium bromide to serve as the loading control (middle panel). The liver homogenates were also used for Western-blot
analysis for the HBV core protein (second panel from the bottom) and the b-actin (bottom panel). The latter served as the loading control. (B)
Suppression of the effects of poly(I:C) on HBV by anti-IFN-a/b antibodies in transgenic mice. HBV transgenic mice were injected with 250 mg control
IgG or anti-IFN-a/b antibodies followed by injection with poly(I:C). These mice were then sacrificed for the analysis of HBV DNA (top panel), HBV RNA
(middle two panels), and the core protein and b-actin (bottom two panels). Two mice were used for each experiment for confirmation of the results.
doi:10.1371/journal.ppat.1002159.g001
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To test this possibility, HBV DNA fragments containing enhancer I
and its overlapping X promoter (ENI/Xp) or enhancer II and its
overlapping C promoter (ENII/Cp) were linked to the firefly
luciferase reporter (Figure 3A). These DNA constructs were
delivered together with the 1.3mer HBV genomic DNA into the
mouse liver by hydrodynamic injection. Poly(I:C) decreased the
expression of the firefly luciferase approximately three-fold when
the ENI/Xp reporter construct was co-injected with 0 or 20 mg
1.3mer HBV genomic DNA. However, it increased the expression
level of the luciferase three to four-fold when the reporter construct
was co-injected with 8 mg 1.3mer HBV genome (Figure 3B). In
contrast, poly(I:C) reduced the expression level of the luciferase
reporter from the ENII/Cp construct, regardless of whether this
reporter construct was co-injected with 0, 8 or 20 mg HBV genomic
DNA (Figure 3C). These results indicated that poly(I:C) most likely
activated HBV gene expression when the HBV DNA level was low
by activating the ENI/Xp complex. Since poly(I:C) could not
activate the ENI/Xp complex in the absence of HBV genome
(Figure 3B), this result also indicated an essential role of a low HBV
genomic DNA level for poly(I:C) to exert its enhancing effect. Note
that, in the absence of poly(I:C), the expression level of luciferase
from the ENI/Xp reporter construct was higher in the presence of
20 mg HBV genomic DNA, and its expression level from the ENII/
Cp reporter construct was higher in the absence of HBV DNA. The
reason for these differences is unclear, but it might be related to the
activities of HBV gene products on ENI/Xp and ENII/Cp
complexes [11,12,13].
The ENI/Xp complex consists of multiple transcription factor
binding sites [10,14]. To further identify the IFN-a/b responsive
element in this complex, we conducted the deletion-mapping
experiments. The deletion of the sequence upstream of nt. 1136
was sufficient to abolish the stimulatory effect of poly(I:C) on the
ENI/Xp complex (Figure 3D), suggesting that the IFN-a/b
responsive element resides at nt. 1115–1136. This sequence has
previously been shown to contain HNF3 and STAT3 transcription
factor binding sites [15,16,17]. To test whether the HNF3 binding
site was indeed the IFN-a/b responsive element, we introduced
mutations, which have previously been shown to abolish the
HNF3 binding [15], into the ENI enhancer (Figure 3A). These
mutations indeed abolished the response of ENI/Xp to IFN-a/b,
confirming the role of the HNF3 binding site in mediating the
effect of IFN-a/b (Figure 3D).
Induction of HNF3c by IFN-a/b to stimulate HBV gene
expression and replication in mice with low HBV levels
There are three isoforms of HNF3, which are HNF3a, HNF3b
and HNF3c. All these three isoforms could bind to the HNF3 site
Figure 2. Viral load-dependent effect of IFN- a/b on HBV in mice. (A) Viral load-dependent effect of poly(I:C) on HBV. Nine-week old, male
naı ¨ve mice were hydrodynamically injected with 4, 8, 14, 20, 24 or 32 mg 1.3mer HBV genomic DNA via the tail vein. Three days after injection, mice
with matched serum HBeAg levels in each group were selected and injected with saline or 200 mg poly(I:C). All of the mice were sacrificed 4 days after
the hydrodynamic injection. The levels of HBV RI DNA (top panel), RNA (middle two panels) and the core protein and b-actin (bottom two panels)
were then analyzed. (B) Anti-IFN-a/b antibodies abolished the effects of poly(I:C) on HBV in mice hydrodynamically injected with 1.3mer HBV DNA.
Experiments were conducted as described in Figure 1B, with the exception that mice were injected with 8 mgo r2 0mg 1.3mer HBV genomic DNA.
doi:10.1371/journal.ppat.1002159.g002
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expression of these three HNF3 isoforms was affected by poly(I:C),
we conducted the Western-blot analysis on the nuclear extracts of
the mouse liver. While poly(I:C) had no effect on the levels of
HNF3a, HNF3b and the control lamin-b protein in the liver of all
four of our HBV transgenic mouse lines, poly(I:C) specifically
increased the level of HNF3c in Tg08 and Tg31 mice but not in
Tg05 and Tg38 mice (Figure 4A). To further study the role of
these three different HNF3 isoforms on the HBV ENI enhancer
activity, the expression plasmids for these three different isoforms
were separately co-transfected with the ENI/Xp reporter into
Huh7 cells, a human hepatoma cell line. The over-expression of
HNF3c, but not HNF3a or HNF3b, could enhance the ENI/Xp
activity in a dose-dependent manner (Figure 4B).
The results suggested that IFN-a/b might induce the expression
of HNF3c to activate the ENI enhancer in mice with a low HBV
level. To test this possibility, we decided to use the shRNA to
suppress the expression of HNF3c. We first verified that the
HNF3c shRNA could indeed suppress the expression of HNF3c
and reduce the ENI/Xp activity in Huh7 cells (Figure S4). We
next co-delivered the expression plasmid of this HNF3c shRNA
with the ENI/Xp reporter construct and 8 mg 1.3mer HBV DNA
into the mouse liver by hydrodynamic injection. Poly(I:C) could
activate the HBV ENI/Xp complex in the presence of the control
Figure 3. Effects of poly(I:C) on HBV ENI/Xp and ENII/Cp in mice. (A) Illustration of the reporter constructs. The HNF3 binding sequence in the
ENI enhancer and the consensus HNF3 binding sequence are also shown. The mutations introduced into 1115-mu-luc are shown in boldface lower-
case letters. Arrows indicate the transcription start sites of the X RNA and the precore protein (PC) RNA. (B) Analysis of the ENI/Xp activity. pGL-3-
1115-luc, which contains the HBV ENI/Xp complex that was linked to the luciferase reporter, was co-delivered with 0, 8 or 20 mg 1.3mer HBV into the
mouse liver by hydrodynamic injection. A renilla luciferase reporter construct pRL-SV40 was also included in the injection to monitor the transfection
efficiency. In all the experiments, if it is necessary, the vector control was included in the injection to ensure that the total amount of DNA used for the
injection was the same between different samples. Forty-two hours after injection, mice were treated with saline (grey bar) or poly(I:C) (empty bar)
and sacrificed six hours later for the isolation of liver for the dual luciferase assay. The firefly luciferase activity was normalized against the renilla
luciferase activity, which was not significantly affected by poly(I:C). The firefly luciferase activity in the absence of 1.3mer HBV DNA and poly(I:C) was
arbitrarily defined as 100%. The results represent the mean6S.D. of three independent experiments. (C) Analysis of the ENII/Cp activity. Experiments
were conducted as described in (B), with the exception that pGL-3-ENII-luc was used as the reporter. (D) Deletion-mapping analysis of the ENI/Xp
complex. The reporter constructs were co-injected with 8 mg 1.3mer HBV DNA into mice. The experiments were conducted as described in (B).
*, p,0.05; **, p,0.01.
doi:10.1371/journal.ppat.1002159.g003
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Similarly, the activation effect of poly(I:C) on HBV DNA
replication and RNA transcription was also abolished by the
HNF3c shRNA in mice injected with 8 mg 1.3mer HBV DNA
(Figure 4D). These results demonstrated that the enhancing effect
of IFN-a/b on HBV replication was mediated by HNF3c.
Activation of STAT3 by IFN-a/b to stimulate HBV gene
expression and replication in mice with low HBV levels
Previous studies indicated that HNF3 and STAT3 could bind to
each other and cooperatively stimulate the HBV ENI enhancer
[17]. Our finding that IFN-a/b induced the expression of HNF3c
to stimulate the HBV ENI enhancer prompted us to examine
whether IFN-a/b also affects STAT3 in mice with a low HBV
level. Although poly(I:C) had no effect on STAT3 in Tg05 mice
that produced a high level of HBV, it activated STAT3 in Tg08
mice, which produced a low level of HBV, as evidenced by the
increased level of phosphorylated STAT3 (p-STAT3) and its
association with the nuclear fraction (Figure 5A). To further
determine the role of STAT3 in mediating the effect of IFN-a/b
on HBV gene expression, we also conducted the shRNA-
knockdown experiment to suppress the expression of STAT3.
We first analyzed the effect of the STAT3 shRNA and
demonstrated that it could reduce the expression level of STAT3
by approximately 40% and a similar level of the ENI/Xp activity
in a reporter assay in Huh7 cells (Figure S5). We then injected
mice with the expression plasmid for the STAT3 shRNA or a
control shRNA, the ENI/Xp reporter construct and 8 mg HBV
genomic DNA, and analyzed the effect of poly(I:C) on the ENI/
Xp activity. The STAT3 shRNA reduced the activation effect of
poly(I:C) on the ENI/Xp complex (Figure 5B). Similar to the
Figure 4. Effects of HNF3 on HBV replication. (A) Western-blot analysis for the expression of HNF3 isoforms. Liver nuclear extracts of HBV
transgenic mice with (+) or without (2) poly(I:C) injection were analyzed for HNF3a, HNF3b, HNF3c, and lamin-b using their respective antibodies. (B)
Effects of HNF3a, HNF3b and HNF3c on HBV ENI/Xp activities in Huh7 cells. The ENI/Xp reporter construct pGL-3-1115-luc as well as the renilla
luciferase reporter was co-transfected with the indicated amounts of the expression plasmid for HNF3a, HNF3b or HNF3c into Huh7 cells. The control
expression vector pRc/CMV was used to ensure that the total amount of DNA used in the transfection was the same among different experiments.
The luciferase activities were determined as described in the Figure 3 legend. (C) Effects of HNF3c on the ENI/Xp complex in mice. Nine-week old
naı ¨ve mice were hydrodynamically injected with the ENI/Xp reporter construct, 8 mg 1.3mer HBV and the expression plasmid for either the control
shRNA or the HNF3c shRNA. Forty-two hours later, mice were further injected with poly(I:C) or saline. Mice were sacrificed six hours later for the
isolation of liver for the dual luciferase assay. Values represent means6S.D. of three independent experiments. The reporter activity in the absence of
poly(I:C) was arbitrarily defined as 100%. (D) Effects of HNF3c on HBV replication in mice. Naı ¨ve mice were co-injected with 8 mg 1.3mer HBV and the
expression plasmid for the control shRNA or HNF3c shRNA, treated with saline or poly(I:C) and sacrificed for the isolation of liver for HBV DNA and
RNA analyses. Two mice were analyzed for each experiment for verification of the results.
doi:10.1371/journal.ppat.1002159.g004
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also partially reduced the enhancing effect of poly(I:C) on HBV
DNA replication and RNA transcription (Figure 5C). These results
indicated that STAT3 also played an important role in mediating
the enhancing effect of IFN-a/b on HBV gene expression. The
lack of complete inhibition of the effects of poly(I:C) by the STAT3
shRNA was probably due to the inefficiency of this shRNA to
knockdown the expression of STAT3 (Figure S5).
Kinetics of HBV replication in mice injected with high and
low doses of HBV DNA
The observation that the effect of IFN-a/b on HBV is
dependent on viral load prompted us to investigate how that
effect may affect viral growth in vivo. We injected mice with either
4 mgo r2 0mg1.3mer HBV genomic DNA and analyzed HBV
surface antigen (HBsAg) and DNA levels in the mouse serum over
a seven-week period of time. Although mice injected with 20 mg
HBV DNA produced initially a higher serum level of HBsAg, this
antigen became undetectable after a week. In contrast, mice
injected with 4 mg HBV DNA produced a lower-level of surface
antigen that persisted for well over a month (Figure 6A).
Importantly, this prolonged antigenemia was abolished if mice
injected with 4 mg HBV DNA were also injected with anti-IFN-a/
b antibodies on a weekly basis, indicating a role of IFN-a/b in
maintaining antigenemia. In contrast, although anti-IFN-a/b
antibodies slightly increased the level of HBsAg in mice injected
with 20 mg HBV DNA one week after DNA injection, they did not
prolong antigenemia, indicating the possible involvement of other
factors in limiting viral persistence. Since HBsAg could be masked
by the antibodies that it elicited, we also analyzed the serum HBV
DNA levels. Mice injected with 20 mg HBV DNA produced a
higher level of serum HBV DNA than mice injected with 4 mg
HBV DNA within the first four days after injection. However, this
difference was not observed one week after injection. Furthermore,
the serum HBV DNA level of mice injected with 20 mg DNA
declined rapidly thereafter and became undetectable after three
Figure 5. Analysis of STAT3 in HBV mice. (A) Western-blot analysis of STAT3 in HBV transgenic mice. Tg05 or Tg08 HBV transgenic mice with (+)
or without (2) poly(I:C) injection were sacrificed and the liver was isolated for Western-blot analysis. (B) Effect of STAT3 on the ENI/Xp activity in mice.
Experiments were conducted as described in the Figure 4C legend, with the exception that the expression plasmid for HNF3c shRNA was replaced
with that for STAT3 shRNA. (C) Effects of STAT3 on HBV replication in mice. Similar to (B), experiments were conducted as described in the Figure 4D
legend, with the exception that the expression plasmid for HNF3c shRNA was replaced with that for STAT3 shRNA.
doi:10.1371/journal.ppat.1002159.g005
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period of time in mice injected with 4 mg DNA (Figure 6B).
Similarly, if mice injected with 4 mg HBV DNA were also injected
with anti-IFN- a/b antibodies, their serum viral DNA level also
became undetectable after three weeks. The anti-IFN-a/b
antibodies had little effect on the serum HBV DNA level in mice
injected with 20 mg HBV DNA, except at the earliest time point.
When the alanine aminotransferase (ALT) was analyzed to
monitor liver injury, high levels of ALT were observed only
within the first few days, most likely caused by the hydrodynamic
injection, which causes liver injury (Figure S6). The ALT levels
were low after that, indicating minimal liver injuries. These results
indicated that the low-dose inoculation of the HBV DNA could
lead to a more persistent viral replication and this persistence was
dependent on IFN-a/b.
Discussion
Interferons are thought to play an important role in the control
of viral infections. Indeed, previous studies using transgenic mice
that produced a high level of HBV indicated that interferons could
suppress HBV replication [18]. Our observation that IFN-a/b
could enhance HBV replication in mice that produced a low level
of HBV is thus rather intriguing. Our results indicated that this
enhancement was due to the activation of the HNF3c gene and
STAT3, which then stimulate the HBV ENI enhancer activity.
The induction of HNF3c by IFN-a/b requires the presence of a
low level of HBV, as such induction was not observed in the
presence of a high level of HBV DNA (Figure 4A) or in naı ¨ve mice
(data not shown). STAT3 is activated in the presence of a low level
of HBV, but it was not activated in the presence of a high level of
HBV (Figure 5A). Since STAT3 can also be activated by IFN- a/b
in hepatocytes in the absence of HBV [19,20], it appears that
HBV at a high replication level can prevent the activation of
STAT3 by IFN-a/b. These observations indicate an interesting
interplay between HBV and the interferon signaling pathway. A
model of how IFN-a/b enhances HBV replication in illustrated in
Figure 7. In this model, the binding of IFN-a/b to its receptor
activates STAT3, likely due to the phosphorylation by JAK, which
is associated with the IFN-a/b receptor and is activated upon
binding of IFN-a/b to its receptor. In the mean time, the activated
interferon signaling pathway also interacts with HBV to induce the
expression of HNF3c, which then binds cooperatively with
STAT3 to the HBV ENI enhancer to stimulate HBV gene
expression and viral replication. How HBV may interact with the
JAK-STAT signaling pathway to induce the expression of HNF3c
is still not clear. This effect is independent of the HBx protein,
since Tg31 mice carried the X-null HBV genome but yet HNF3c
could be induced by poly(I:C) in this mouse line (Figure 4A).
Clearly, if another HBV gene product such as that of the S, C or P
gene is involved, this gene product must exert a dose-dependent
effect since only a low replication level of HBV could induce
HNF3c.
The observation that IFN-a/b enhances HBV replication when
the HBV DNA level is low may represent a mechanism by which
HBV uses to establish its infection in patients, as the viral level is
expected to be low in patients during the early stage of HBV
infection. This possibility is supported by our observation that the
injection of a small amount of HBV genomic DNA into mice
could lead to prolonged viremia in an IFN-a/b-dependent
manner (Figure 6). As our mouse model does not allow the
reinfection of hepatocytes by HBV, it is conceivable that, if
reinfection is possible, viral replication can persist in mice for an
even longer period of time. Indeed, it has been shown that low-
dose (1 or 10 genome-equivalent copies) inoculations of HBV into
chimpanzees would lead to the spread of the virus and result in the
infection of 100% of hepatocytes and prolonged immunopathol-
ogy [21]. In contrast, the inoculation of between 10
4 and 10
8
genome copies of the virus led to a limited spread of the virus in
the liver and the speedier clearance of the virus. Based on our
findings described in this report, it is conceivable that the initial
IFN-a/b response to the low-level HBV inoculation enhanced
viral replication and spread and prolonged viral infection in
chimpanzees.
Although the injection of IFN- a/b antibodies could suppress
viral persistence in mice injected with 4 mg HBV DNA, the
injection of IFN-a/b antibodies did not prolong viral persistence
in mice injected with 20 mg HBV DNA. This result indicated that
the removal of IFN-a/b alone was not sufficient to maintain viral
persistence when viral load is high. The reason for this is unclear,
but it may involve other factors such as additional cytokines (e.g.,
IFN-c) that may be induced by high HBV load [18].
Recent studies indicated that the HBx protein could bind to
MAVS (also known as IPS-1, VISA or Cardiff), which is an
important adaptor molecular of the RIG-I signaling pathway, to
suppress the induction of IFN-b [22,23]. It has also been reported
that the HBV DNA polymerase could bind to the DDX3 deadbox
RNA helicase to suppress its interaction with TBK1/IKKe and
the induction of IFN-b [24,25]. In contrast to HBV structural
proteins, HBx and the HBV polymerase are produced at a much
lower level during viral replication. For this reason, it is likely that
these two HBV products can only efficiently suppress the
induction of type I interferons when the viral replication level is
high. It is conceivable that the lag period before the effective
concentrations of HBx and polymerase are reached in HBV-
infected cells will allow HBV to use the interferon response to
stimulate its gene expression and replication. However, once HBV
has replicated to a high level and interferons become a negative
regulator for HBV replication, HBx and the viral polymerase will
exert their anti-interferon activities to enhance the survival of the
virus.
IFN-a has been used to treat HBV patients, but it generated
sustained response in only a minority of patients. Our observation
that IFN-a/b could have opposite effects on HBV in a viral load-
dependent manner indicates that viral load may be one of the
reasons why this therapy has generated inconsistent responses in
HBV patients.
Materials and Methods
Ethics statement
Our studies on mice were conducted in accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Our animal protocol
was approved by the Institutional Animal Care and Use
Committee of the University of Southern California.
HBV transgenic mice and DNA plasmids
HBV transgenic mouse lines Tg05 and Tg08 have been
previously described [5,26]. These two mouse lines carried the
1.3mer, over-length wild-type HBV genome. Tg31 and Tg 38 also
carried 1.3mer HBV genome, with the exception that the
expression of X protein was abolished by the introduction of an
A-to-C mutation at nt.1377 to remove the initiation codon of the
X protein and a C-to-T mutation at nt.1398 to introduce a
premature termination codon in the X coding sequence. All of the
experiments were conducted using age-matched male mice with
the B6 genetic background.
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length HBV genome, has been described before [27]. pCMV-
HNF3a, pCMV-HNF3b and pCMV-HNF3c, which express
HNF3a, HNF3b and HNF3c, respectively, have also been
described [15]. The expression plasmids for mouse HNF3c
shRNA, STAT3 shRNA and control shRNA were purchased
from Sigma-Aldrich. The HBV ENI/X reporter constructs pGL-
3-1115-luc, pGL-3-1136-luc, pGL-3-1167-luc and pGL-3-1203-
luc, which contained nt.1115–1355, 1136–1355, 1167–1355 and
1203–1355, respectively, of the HBV genome, were generated by
PCR amplification of the HBV DNA fragment for cloning into the
pGL3-basic vector (Promega). The plasmid pGL-3-ENII-luc was
constructed by insertion the ENII/core promoter complex
(nt.1403–1803) into the pGL3-basic vector. pRL-SV40 (Promega),
which expresses the renilla luciferase, was included in the
transfection studies to serve as the internal control to monitor
the transfection efficiency.
Injection with poy(I:C)
Age and HBeAg-matched male HBV transgenic mice or naı ¨ve
mice were injected intravenously with 200 ml saline with or
without poly(I:C) (200 mg/mouse). Mice were sacrificed 24 hours
later. The serum was collected and the liver was harvested and
stored at 280uC for analyses.
Hydrodynamic injection of p1.36HBV
Nine-week old male mice were injected via the tail vein with
p1.36HBV in 5–8 seconds in a volume of saline equivalent to 8%
of the body weight of the mouse. In all the injection experiments,
Figure 6. Analysis of HBV replication in mice. The sera of eight mice injected with 4 mg 1.3mer HBV DNA, six mice injected with 20 mg HBV DNA,
3 mice co-injected with 20 mg 1.3mer HBV DNA and anti-IFN-a/b antibodies, and 3 mice co-injected with 4 mg 1.3mer HBV DNA and anti-IFN-a/b
antibodies, were collected at the time points indicated and analyzed for HBsAg by ELISA (A) and HBV DNA by real-time PCR (B). For mice treated with
anti-IFN-a/b antibodies, 250 mg antibodies were injected immediately after DNA injection and thereafter on a weekly basis. The results shown in (B)
represent the mean6S.D. of all of the mice used in each group. The results shown in (A) represent the mean6S.D. of the mice that were still positive
for HBsAg at that particular time point.
doi:10.1371/journal.ppat.1002159.g006
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the total amount of DNA used for injection is identical among
different mice. 24 hours after the hydrodynamic injection, the
serum was collected and HBeAg was assayed by ELISA. Mice
matched by body weight, age and HBeAg levels were used for
injection with poly(I:C).
Antibodies
Rabbit anti-mouse IFN-a (PBL, New Jersey) and hamster anti-
mouse IFN-b (Biolegend, San Diego) antibodies were used in this
study. Purified rabbit IgG (Cell Signaling Tech.) and hamster IgG
(Abcam) were used as the control antibodies. Rabbit anti-HNF3a
(Abcam), anti-HNF3b (Cell Signaling Tech.), anti-HNF3c (Sig-
ma–Aldrich Co.), anti-STAT3 (Cell Signaling Tech.), anti-phosph-
STAT3(Tyr705) (Cell Signaling Tech.) and anti-lamin-b (Abcam)
antibodies were used for Western-blot.
Southern-, Northern- and Western-blot analyses
Liver tissues were homogenized in DNA lysis buffer (20 mM
Tris-HCl, pH 7.0, 20 mM EDTA, 50 mM NaCl, 0.5% SDS),
incubated for 16 hours at 37uC with proteinase K (600 mg/ml)
and then phenol/chloroform extracted for the isolation of DNA.
The HBV RI DNA in the core particles was isolated using our
previous protocol [27]. For RNA isolation, liver tissues were
homogenized in Trizol (Invitrogen) and total RNA was isolated
following the manufacturer’s protocol. Both Southern and
Northern blot analyses were conducted using the
32P-labeled
HBV DNA probe. For Western-blot analysis, liver tissues were
homogenized in the RIPA solution (10 mM Tris-HCl, pH 7.0,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, and
0.1% sodium dodecyl sulfate) and, after a brief centrifugation to
remove cell debris, the protein concentrations were determined by
Bradford BCA (Biorad) and the Western blot was performed using
our previous procedures [28].
Real-time PCR analysis of serum HBV DNA
10 ml mouse serum was added into 100 ml lysis buffer (20 mM
Tris-HCl, 20 mM EDTA, 50 mM NaCl, and 0.5%SDS) contain-
ing 27 mg proteinase K. After incubation at 65uC overnight, viral
DNA was isolated by phenol/chloroform extraction and ethanol
precipitation. The DNA pellet was rinsed with 70% ethanol and
resuspended in 10 ml TE (10 mM Tris-HCl [pH 7.0], 1 mM
EDTA). For hydrodynamic injection studies, 10 ml serums was
digested with 10 mg DNase I and micrococcal nuclease for 30 min
at 37uC to remove free DNA. HBV DNA was then isolated as
described above. For HBV real-time PCR analysis, the following
primers were used: forward primer, 1552-CCGTCTGTGCCTT-
CTCATCTG-1572; and reverse primer, 1667-AGTCCTCTTA-
TGTAAGACCTT-1646. The TaqMan probe used was 1578-
CCGTGTGCACTTCGCTTCACCTCTGC-1603. The assays
were performed as described [29].
The luciferase reporter assay
The reporter constructs were delivered into the mouse liver by
hydrodynamic injection. Nine-week old male mice were used in
the studies. Twenty-four hours after injection, the serum was
Figure 7. Mechanism of the activation of HBV replication by IFN- a/b when the HBV level is low. IFNR, interferon receptor; JAK, Janus
kinase; p-Stat3, phosphorylated Stat3.
doi:10.1371/journal.ppat.1002159.g007
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body weight and the HBeAg level were injected intravenously with
200 ml saline with or without poly(I:C) (200 mg/mouse) at
42 hours after hydrodynamic injection and sacrificed 6 hours
later. The mouse liver was isolated and stored at 280uC. The
firefly luciferase and the renila luciferase activities were measured
using the dual luciferase assay kit (Promega). The firefly luciferase
activities were normalized against the renilla luciferase activities,
which served as the internal control. All of the experiments were
repeated at least three times.
Serum ALT and ELISA assays
Serum ALT levels were measured using the ALT kit (Cayman
Chemical Company, USA). HBsAg and HBeAg were measured
using their respective ELISA kit (International Immuno-Diagnos-
tics, CA). All of these assays were conducted following the
manufacturers’ instructions.
Supporting Information
Figure S1 Replication of HBV in transgenic mice. (A)
HBV DNA and RNA levels in the mouse liver. Top panel,
ethidium bromide staining of the chromosomal DNA, which
served as the loading control for Southern blot; second panel from
the top, Southern-blot analysis of HBV DNA; third panel from the
top, Northern-blot analysis of HBV RNA; bottom panel, ethidium
bromide staining of the RNA gel to serve as the loading control.
The HBV DNA replicative intermediates (RI) appeared as a smear
on the gel. C and S indicate HBV C gene and S gene transcripts,
respectively. The locations of 28S and 18S rRNAs are also
indicated. (B) HBV DNA levels in the sera of different
transgenic mouse lines. Nine-week old male HBV transgenic
mice were used for the studies. HBV DNA was extracted from the
serum and quantified by real-time PCR.
(TIF)
Figure S2 Effects of poly(I:C) on HBV transgenic mice.
(A) Induction of 29,59-OAS in the mouse liver by
poly(I:C). Total liver RNA was isolated from mice 24 hours
after injection with saline (2) or poly(I:C) (+) and analyzed by
semi-quantitative RT-PCR for 29,59-OAS RNA and GAPDH
RNA. The latter served as the control. (B) Suppression of the
interferon response in the mouse liver by the anti-IFN-
a/b antibodies. HBV transgenic mice were injected intrave-
nously with the control IgG or anti-IFN-a/b antibodies (500 mg/
mouse) and then with 200 mg poly(I:C) 16 hours later. Mice were
sacrificed 24 hours after the poly(I:C) injection for the isolation of
total liver RNA, which was used for semi-quantitative RT-PCR
for the analysis of 29,59-OAS RNA and GAPDH RNA. Mice
without the injection of poly(I:C) and antibodies were also
included in the studies to serve as the control. (C) Suppression
of poly(I:C)-induced HBV replication in Tg31 HBV
transgenic mice by anti-IFN-a/b antibodies. Tg31 HBV
transgenic mice were injected intravenously with the control IgG
(lane 2), anti-IFN-a and anti-IFN-b antibodies together (lane 3),
the anti-IFN-a antibody alone (lane 4), or the anti-IFN-b antibody
alone (lane 5), followed by the injection with 200 mg poly(I:C)
16 hours later (lanes 2–5). Mice were sacrificed 24 hours after the
injection with poly(I:C) for the analysis of HBV DNA (top panel),
HBV RNA (middle two panels), and the core protein and b-actin
(bottom two panels) in the liver. (D) Effects of IFN-a/b on
HBV replication in Tg05 and Tg31 mice. Tg05 and Tg08
mice were injected with PBS, IFN- (1.4610
5 units) or IFN-b
(1.6610
5 units) and sacrificed 24 hours later for the isolation of
liver for analysis RNA (second panel from the top). The ribosomal
RNAs (third panel from the top) and GAPDH RNA (bottom
panel) were used as the loading control for Northern-blot analysis.
(E) Prolonged effect of poly(I:C) on HBV replication.
Tg05 and Tg08 mice were injected with poly(I:C) on a daily basis
and sacrificed at the indicated time points for HBV DNA and
RNA analysis as described in (D).
(TIF)
Figure S3 Quantification of HBV titers in the sera of
mice injected with HBV DNA. Mice were injected with the
indicated amount of the 1.3mer HBV DNA in phosphate-buffered
saline (PBS). Four days later, mouse sera were treated with DNase
I and micrococcal nuclease to remove free DNA. The HBV virion-
associated DNA was then extracted and analyzed by real-time
PCR. The results represent the average of at least three different
mice.
(TIF)
Figure S4 Effects of HNF3c on the ENI/Xp activity in
Huh7 cells. Huh7 cells were co-transfected with the ENI/Xp
reporter construct and the expression plasmid for the control
shRNA or the HNF3c shRNA for forty-eight hours and then lysed
for Western-blot analysis for HNF3c and lamin-b (top panel). The
latter is a nuclear protein and served as the loading control. The
plasmid pRL-SV40, which expresses renilla luciferase, was
included in the transfection to monitor the transfection efficiency.
Cell lysates were analyzed for the luciferase activities using the
dual luciferase assay (Promega) (bottom panel).
(TIF)
Figure S5 Effects of STAT3 on the ENI/Xp activity in
Huh7 cells. The experiments were conducted as described in the
legend to Figure S4, with the exception that the HNF3c shRNA
was replaced with the STAT3 shRNA. Top panel, Western-blot
analysis of STAT3 and a-actin; bottom panel, relative firefly
luciferase activities.
(TIF)
Figure S6 Analysis of ALT levels in mice injected with
HBV DNA. The serum samples collected from mice shown in
Fig. 6 were analyzed for the ALT levels using the ELISA kit. The
numerical ALT levels at individual time points are shown in the
Table. N.D., not determined.
(TIF)
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